{
    "root": "5092af6c-29e7-40fe-9e25-46ab5de48bbb",
    "code": "34391-3",
    "codeSystem": "2.16.840.1.113883.6.1",
    "displayName": "HUMAN PRESCRIPTION DRUG LABEL",
    "name": "Nilotinib",
    "value": "20250523",
    "ingredients": [
        {
            "name": "NILOTINIB",
            "code": "F41401512X",
            "chebi_id": "http://purl.obolibrary.org/obo/CHEBI_52172"
        },
        {
            "name": "SILICON DIOXIDE",
            "code": "ETJ7Z6XBU4",
            "chebi_id": "http://purl.obolibrary.org/obo/CHEBI_30563"
        },
        {
            "name": "CROSPOVIDONE (120 .MU.M)",
            "code": "68401960MK"
        },
        {
            "name": "GELATIN, UNSPECIFIED",
            "code": "2G86QN327L",
            "chebi_id": "http://purl.obolibrary.org/obo/CHEBI_5291"
        },
        {
            "name": "LACTOSE MONOHYDRATE",
            "code": "EWQ57Q8I5X",
            "chebi_id": "http://purl.obolibrary.org/obo/CHEBI_17716"
        },
        {
            "name": "MAGNESIUM STEARATE",
            "code": "70097M6I30",
            "drugbank_id": "https://go.drugbank.com/drugs/DB14077"
        },
        {
            "name": "FERRIC OXIDE RED",
            "code": "1K09F3G675",
            "chebi_id": "http://purl.obolibrary.org/obo/CHEBI_50819"
        },
        {
            "name": "TITANIUM DIOXIDE",
            "code": "15FIX9V2JP",
            "chebi_id": "http://purl.obolibrary.org/obo/CHEBI_32234"
        },
        {
            "name": "FERRIC OXIDE YELLOW",
            "code": "EX438O2MRT",
            "chebi_id": "http://purl.obolibrary.org/obo/CHEBI_50819"
        },
        {
            "name": "POLOXAMER 188",
            "code": "LQA7B6G8JG",
            "chebi_id": "http://purl.obolibrary.org/obo/CHEBI_32026"
        },
        {
            "name": "AMMONIA",
            "code": "5138Q19F1X",
            "chebi_id": "http://purl.obolibrary.org/obo/CHEBI_16134"
        },
        {
            "name": "FERROSOFERRIC OXIDE",
            "code": "XM0M87F357",
            "chebi_id": "http://purl.obolibrary.org/obo/CHEBI_50821"
        },
        {
            "name": "PROPYLENE GLYCOL",
            "code": "6DC9Q167V3",
            "chebi_id": "http://purl.obolibrary.org/obo/CHEBI_13643"
        },
        {
            "name": "SHELLAC",
            "code": "46N107B71O"
        },
        {
            "name": "D&C RED NO. 7",
            "code": "ECW0LZ41X8"
        },
        {
            "name": "FD&C BLUE NO. 2",
            "code": "L06K8R7DQK"
        },
        {
            "name": "FD&C RED NO. 40",
            "code": "WZB9127XOA"
        },
        {
            "name": "ALUMINUM OXIDE",
            "code": "LMI26O6933",
            "chebi_id": "http://purl.obolibrary.org/obo/CHEBI_25741"
        }
    ],
    "indications": {
        "text": "nilotinib kinase inhibitor indicated treatment : adult pediatric patients greater equal 1 year age newly diagnosed philadelphia chromosome positive chronic myeloid leukemia ( ph+ cml ) chronic phase . ( 1.1 ) adult patients chronic phase ( cp ) accelerated phase ( ap ) ph+ cml resistant intolerant prior therapy included imatinib . ( 1.2 ) pediatric patients greater equal 1 year age ph+ cml-cp cml-ap resistant intolerant prior tyrosine-kinase inhibitor ( tki ) therapy . ( 1.3 )",
        "doid_entities": [
            {
                "text": "chronic myeloid leukemia (DOID:8552)",
                "doid_id": "http://purl.obolibrary.org/obo/DOID_8552"
            },
            {
                "text": "myeloid leukemia (DOID:8692)",
                "doid_id": "http://purl.obolibrary.org/obo/DOID_8692"
            },
            {
                "text": "leukemia (DOID:1240)",
                "doid_id": "http://purl.obolibrary.org/obo/DOID_1240"
            },
            {
                "text": "cml (DOID:1036)",
                "doid_id": "http://purl.obolibrary.org/obo/DOID_1036"
            }
        ],
        "orphanet_entities": [
            {
                "disease": "chronic myeloid leukemia",
                "orphanet_id": "http://www.orpha.net/ORDO/Orphanet_521"
            }
        ]
    },
    "contraindications": {
        "text": "recommended adult dose : newly diagnosed ph+ cml-cp : 300 mg orally twice daily . resistant intolerant ph+ cml-cp cml-ap : 400 mg orally twice daily . ( 2.1 ) recommended pediatric dose : newly diagnosed ph+ cml-cp ph+ cml-cp resistant intolerant prior tki therapy : 230 mg/m 2 orally twice daily , rounded nearest 50 mg dose ( maximum single dose 400 mg ) . ( 2.1 ) full dosing instructions dose- reduction instructions toxicity . ( 2.1 ) reduce starting dose patients baseline hepatic impairment . ( 2.7 ) eligible newly diagnosed adult patients ph+ cml-cp received nilotinib capsules minimum 3 years achieved sustained molecular response ( mr4.5 ) patients ph+ cml-cp resistant intolerant imatinib received nilotinib capsules least 3 years achieved sustained molecular response ( mr4.5 ) may considered treatment discontinuation . ( 2.2 , 2.3 , 5.16 )",
        "doid_entities": [],
        "orphanet_entities": []
    },
    "warningsAndPrecautions": "nilotinib capsules , 50 mg available oral hard gelatin capsules yellow opaque body light orange opaque cap imprinted \u201c apo n50 \u201d black ink . supplied follows : bottles 120 ndc 60505-3803-7 nilotinib capsules , 150 mg available oral hard gelatin capsules red opaque body red opaque cap imprinted \u201c apo n150 \u201d black ink . supplied follows : outer carton containing 4 inner cartons ( 4x28 ) ndc 60505-3801-2 inner carton 28 capsules ( 2x14 ) ndc 60505-3801-3blisters 28 capsules ( 2x14 ) ndc 60505-3801-0 nilotinib capsules , 200 mg available oral hard gelatin capsules yellow opaque body yellow opaque cap imprinted \u201c apo n200 \u201d maroon ink . supplied follows : outer carton containing 4 inner cartons ( 4x28 ) ndc 60505-3802-2 inner carton 28 capsules ( 2x14 ) ndc 60505-3802-3 blisters 28 capsules ( 2x14 ) ndc 60505-3802-0 inner carton contains two blister cards 14 capsules , dosing two morning two evening 12 hour intervals 7 day period . store 20\u00b0c 25\u00b0c ( 68\u00b0f 77\u00b0f ) ; excursions permitted 15\u00b0c 30\u00b0c ( 59\u00b0f 86\u00b0f ) [ usp controlled room temperature ] .",
    "adverseReactions": "nilotinib capsules contraindicated patients hypokalemia , hypomagnesemia , long qt syndrome [ boxed warning ] .",
    "indications_original": "Nilotinib is a kinase inhibitor indicated for the treatment of: Adult and pediatric patients greater than or equal to 1 year of age with newly diagnosed Philadelphia chromosome positive chronic myeloid leukemia (Ph+ CML) in chronic phase. ( 1.1 ) Adult patients with chronic phase (CP) and accelerated phase (AP) Ph+ CML resistant to or intolerant to prior therapy that included imatinib. ( 1.2 ) Pediatric patients greater than or equal to 1 year of age with Ph+ CML-CP and CML-AP resistant or intolerant to prior tyrosine-kinase inhibitor (TKI) therapy. ( 1.3 )",
    "contraindications_original": "Recommended Adult Dose: Newly diagnosed Ph+ CML-CP: 300 mg orally twice daily. Resistant or intolerant Ph+ CML-CP and CML-AP: 400 mg orally twice daily. ( 2.1 ) Recommended Pediatric Dose: Newly Diagnosed Ph+ CML-CP or Ph+ CML-CP resistant or intolerant to prior TKI therapy: 230 mg/m 2 orally twice daily, rounded to the nearest 50 mg dose (to a maximum single dose of 400 mg). ( 2.1 ) See Dosage and Administration for full dosing instructions and dose- reduction instructions for toxicity. ( 2.1 ) Reduce starting dose in patients with baseline hepatic impairment. ( 2.7 ) Eligible newly diagnosed adult patients with Ph+ CML-CP who have received nilotinib capsules for a minimum of 3 years and have achieved a sustained molecular response (MR4.5) and patients with Ph+ CML-CP resistant or intolerant to imatinib who have received nilotinib capsules for at least 3 years and have achieved a sustained molecular response (MR4.5) may be considered for treatment discontinuation. ( 2.2 , 2.3 , 5.16 )",
    "warningsAndPrecautions_original": "Nilotinib capsules, 50 mg are available for oral administration as hard gelatin capsules with yellow opaque body and light orange opaque cap imprinted \u201cAPO N50\u201d in black ink. They are supplied as follows:\n                  Bottles of 120 \u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0NDC 60505-3803-7\n                  Nilotinib capsules, 150 mg are available for oral administration as hard gelatin capsules with red opaque body and red opaque cap imprinted \u201cAPO N150\u201d in black ink. They are supplied as follows:\n                  \n                     \n                     Outer Carton containing 4 inner cartons (4x28) \u00a0NDC 60505-3801-2\n                  Inner Carton of 28 capsules (2x14)  NDC 60505-3801-3Blisters of 28 capsules (2x14)\u00a0NDC 60505-3801-0\n                  Nilotinib capsules, 200 mg are available for\u00a0 oral administration as\u00a0 hard gelatin capsules with yellow opaque body and yellow opaque cap imprinted \u201cAPO N200\u201d in maroon ink.\u00a0\u00a0 They are supplied as follows:\n                  Outer Carton containing 4 inner cartons (4x28)                   NDC 60505-3802-2\n                  Inner Carton of 28 capsules (2x14) NDC 60505-3802-3\u00a0 \n                  Blisters of 28 capsules (2x14)                                              NDC 60505-3802-0\n                  Each inner carton contains two blister cards of 14 capsules each, for dosing two in the morning and two in the evening at 12 hour intervals over a 7 day period. \n                  Store at 20\u00b0C to 25\u00b0C (68\u00b0F to 77\u00b0F); excursions permitted from 15\u00b0C to 30\u00b0C (59\u00b0F to 86\u00b0F) [see USP Controlled Room Temperature].",
    "adverseReactions_original": "Nilotinib capsules are contraindicated in patients with hypokalemia, hypomagnesemia, or long QT syndrome [see Boxed Warning].",
    "drug": [
        {
            "name": "Nilotinib",
            "chebi_id": "http://purl.obolibrary.org/obo/CHEBI_52172"
        }
    ]
}